Get started

Covid-19c

BIOV -- FDA approval for COVID-19 clinical trialsBiotech sector is getting hot, especially for companies connected to COVID-19 vaccine and treatments development... BIOV chart looks rip for a breakout with MACD closing in on bullish cross and a major catalyst in the form of FDA approval of its Phase I/II study: FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IND Type B review of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2. The FDA found the Chemistry, Manufacturing and Controls, and other elements of the clinical development program proposed by BioVaxys to be acceptable and provided guidance and feedback supportive of BioVaxys' clinical development plans for CoviDTH. In addition, the FDA indicated that animal toxicity studies for CoviDTH were not required and that the Company could start its clinical development program with a combined Phase I/II study. Based on this feedback, BioVaxys will begin preparation of an IND application to support a Phase I/II safety, dosing, and efficacy study. BioVaxys submitted a Pre-Investigational New Drug ("IND") meeting request and briefing package with the FDA's Center for Biologics Evaluation and Research (CBER) for CoviDTH earlier this year. The Pre-IND review is a critical step in the US regulatory approval process, as it affords an opportunity for study sponsor companies to seek clarification from the FDA on clinical trials design, clinical materials manufacturing, quality controls, etc. "With the guidance we received from this FDA review, BioVaxys is now able to begin preparing its IND," stated BioVaxys President and Chief Operating Officer Ken Kovan. He adds "Although the FDA has indicated that our planned animal tox study is discretionary, we will likely continue with the animal tox study of CoviDTH as it does not interfere with the development time frame and may in fact provide useful data." James Passin, BioVaxys CEO, stated, "We are pleased to advance CoviDTH towards clinical trials, as we believe that mass screening for T cell immunity to Covid-19 will represent a critical tool for public health authorities to address the continued pandemic, as Covid variants continue to circulate and major governments in the southern hemisphere enact new lockdown policies." The Company is not making any express or implied claims that its product has the ability to eliminate, cure, or contain Covid-19 (SARS-CoV-2) at this time.
CSE:BIOVLong
by wealth_bakery
KNR -- Oversold; Double Bottom at .89. On watch for a bounce.KNR has been beaten down but looks way overdone, given they have just raised $8.5 at 1.50 with institutional investors. The company reported respectable $3.3M revenues in Q1 2021. Their BioCloud COVID-19 detection device will be used by the Canadian Olympic delegation at the Tokyo Olympics. The US sales channel is being worked on. Insiders are buying in the open market. Share buyback program is in effect. Bullish MACD divergence on the chart.
NEO:KNRLong
by wealth_bakery
1
UPI -- Fundamentally undervalued; multi-bagger candidate!UPI is ridiculously undervalued at $15M mkt cap and is a potential multi-bagger candidate from these levels. - Close to $10M in revenue in 2020 and is on pace to at least double it — recorded $1M in sales in the first week of June! - Profitable, no debt - Exclusive distributor of the 20-second non-invasive (finger scan) COVID-19 test that is currently undergoing clinical trial at Toronto Pearson Airport and could be a game changer! - Other products include COVID-19 virus elimination tech using UV lights, thermal detection and air filtration - Expanding to the US - Insiders are buying in the open market
ULong
by wealth_bakery
Dyadic and Medytox To Develop Vaccines Against COVID-19 VariantsDyadic and Medytox To Develop Vaccines Against COVID-19 Variants Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines) Exclusive license for Republic of Korea and multiple Southeast Asian countries, if successful Manufacturing protocols to produce vaccines from C1 have been successfully transferred and reproduced at Medytox finance.yahoo.com
NASDAQ:DYAI
by AlenCiken
Reduced recovery time in mild-to-moderate COVID-19 patientsNew Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish standard of care not only reduced recovery time but improved liver health and decreased levels of inflammatory markers. finance.yahoo.com
NASDAQ:CDXC
by AlenCiken
Why $IFMK Skyrocketed in February? indoor dining shutdownsWhy $IFMK Skyrocketed in February There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media. $IFMK shares were buoyed — thanks to discussions and speculation on Twitter and Twitter hashtags at the start of the month. iFresh Inc is an Asian/Chinese grocery supermarket chain in the North-Eastern U.S. providing food and other merchandise hard to find in mainstream grocery stores. The company generates a majority of its revenue from its retail segment. The other positive factor for the $IFMK is the surging Food delivery in NYC as indoor dining shutdowns continue (based out of nyc), due to covid 19. www.benzinga.com twitter.com
I
by AlenCiken
TYME Granted U.S. Patent Claims Treat COVID-19 InfectionsTYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19. Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and any mutations to the viral coat. TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19. TYME-19 is an investigational compound that is not approved in the U.S. for any disease indication. finance.yahoo.com
T
by AlenCiken
1
Potential Development of an Oral COVID-19l VaccineAeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg - Company secures next step to continue to build-out pipeline of assets. - University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19. - Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement. to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine. Under the option agreement entered into with the University, Aeterna has the right to negotiate an exclusive worldwide license to develop this technology for the prevention of coronavirus diseases, including COVID-19. A scientific advice meeting with the German authorities at Paul-Ehrlich Institute has been scheduled by the University to discuss a roadmap towards initiating a first-in-human clinical trial. finance.yahoo.com Aeterna expects to make a decision whether to exercise its option to negotiate a license for that technology by mid 2021.
A
by AlenCiken
Adamis Surges After Submitting Covid Drug to FDAAdamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19 announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific recommendations on Chemistry, Manufacturing and Controls (CMC) and Clinical aspects to be included in the IND. The Company plans to seek government and/or non-government funding to study the treatment and prevention of COVID-19 with Tempol. Tempol has demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity. finance.yahoo.com
A
by AlenCiken
1
Regeneron's Covid Treatment First Drug Authorized By FDAMy last chart: November 22, 2020: Regeneron's Coronavirus Treatment Becomes First Antibody Cocktail to Earn Emergency Use Authorization from FDA (The Motley Fool). Regeneron Covid Drug Gets Emergency OK. Antibody drug cocktail casirivimab and imdevimab are allowed for use by people over age 12 with mild or moderate Covid-19. (the street). If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:REGNLong
by TopgOptions
BLACK SWAN PESSIMISTIC SCENARIO WIG20This pessimistic scenario is based upon current state of healthcare services in Poland which were underfinanced for many years and have very limited resources in qualified personell and equipment. There is significant lack of nurses and doctors in Poland not mentioning available hospital beds which means the system is near its breaking point. Recents countrywide protests could lead to epidemic spread of Covid 19 infection which will soon paralyse healthcare sytem and force goverment to freeze everything.
GPW:FW20Z2020Short
by CashJohny
VST.C -- Gearing up for Wave 2 up move on COVID-19 newsVST has its hand in a number of sectors, including a sizeable holding in FANS (esports/gambling stock) but it has recently gained attention because of its stake in the rapid COVID-19 test manufacturer. Yesterday, they've announced that they are increasing their manufacturing capacity by 5M test kits per month. In the followup webinar, investors were informed of several pending orders with large corporate and government bodies. The company is under NDA at the moment but there will be followup news releases as the orders are fulfilled. Their COVID-19 test has received authorization in a number of major jurisdictions, including most recently Brazil which faces one of the worst COVID-19 outbreaks at the moment. The company reported record numbers in most recent financials, nearly doubling its net income ($4.7M) from the same 6 month period of last year. Technically, yesterday marked a decisive reversal after ~50% retrace from recent high and it appears the chart is gearing up for Wave 2 move that should see re-test (and likely break) through resistance around 1.10. ---------------------------------------------------------------- Victory Square Health Increases Monthly Production of Rapid Covid-19 Test Kits to Meet Increased Demand with New Manufacturing Agreement with Gold Analisa Diagnostica Ltda VANCOUVER, British Columbia, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc./Safetest (“VS Health” or the "Company") – portfolio company of Victory Square Technologies Inc. ("Victory Square") (CSE:VST) (OTC:VSQTF) (FWB:6F6) – is pleased to announce entering into a manufacturing contract for their IgG and IgM Rapid Test Kits for the detection of Covid-19 for sales and distribution globally. The latest manufacturing agreement will allow the company to produce an additional 5,000,000 VS Health Covid-19 Rapid Tests monthly for Global distribution. This additional manufacturing contract will also enable the Company to enter into additional global sales agreements in various industries which have shown interest, including retail, hospitality, pharmaceutical, correctional facilities, casino, border services, education, airport, military, government, and more. “Based on our outreach and discussions, the demand for our exclusive test from distributors around the world is very high,” said Victory Square Health CEO Felipe Peixoto. “Given that demand, this new capacity-building manufacturing contract is a significant boost to our plan to be a positive solution around the world. To that end, Victory Square Health is committed to providing assistance to as many nations as possible through these distribution channels.” The new Victory Square Health/Safetest manufacturer is Gold Analisa Diagnostica Ltda., a Government-recognized manufacturer of bio products in Brazil and has operated for over 30 years. Gold Analisa is ISO 9001: 2015 certified by DNV - DET NORSKE VERITAS in the scope of production, marketing and technical-scientific advisory services for products for in vitro diagnostic use. Gold Analisa has Anvisa's Good Manufacturing and Control Practices certificate with hivital, and also participates in the PNCQ - National Quality Control Program, sponsored by SBAC – Sociedade Brasileira de Análises Clínicas. Gold Analisa has a distribution network that aims to be close to customers, covering the entire national territory of Brazil. “We’re completely energized by this critical new manufacturing contract which will allow Victory Square Health to fulfill the tremendous demand for its exclusive Rapid Test kits on a global scale,” said Shafin Diamond Tejani, CEO of Victory Square Technologies, of which Victory Square Health is a portfolio company. “We are actively working together on other production partnership agreements to further increase our production capacity.”
CSE:VSTLong
by wealth_bakery
Citigroup looks undervalued, but too risky to enter hereI did a deep valuation analysis on Citigroup today, digging into their earnings reports for the last three years as well as analyst estimates for the next 4 quarters. Here are my conclusions. In forward P/S terms, Citigroup is nearly the cheapest it has been in the last three years. However, in forward P/E terms, it's nearly the most expensive it has been in the last three years. The valuation in P/S terms may be more important, because analysts expect the earnings numbers to climb steeply back up to meet the sales numbers within a few years. (Roughly 23% earnings growth rate expected in the next 4 quarters, and nearly 4% growth rate for sales.) However, there are risks. Analysts are predicting a steep drop-off in sales next quarter due to the pandemic's impact on consumer credit, which is sharply down. Then they expect sales to recover from there. However, an alternative scenario is that the pandemic is prolonged and we don't get a vaccine this fall, in which case credit might continue to deteriorate and Citigroup's sales might fall off even more steeply in Q4 than in Q3. I'm also worried about the outlook for the mortgage market. Current housing prices are artificially high, but there's a reckoning coming for residential real estate whenever Congress allows mortgage forbearance to expire. (Expiry is scheduled for August 31, but there's talk of extending it to next year.) If forbearance is extended, then renters and borrowers may not pay, which would hurt bank earnings. If forbearance is allowed to expire, then housing prices will fall and mortgage sales numbers will fall with them. Banks would seem to be in trouble either way, and I'm not certain analysts have accounted for this. Thus, I will not be entering Citigroup here. I expect the narrative around banks to remain negative for the next quarter as bankruptcy and default rates continue to rise and credit continues to deteriorate. There's a good chance we will retest the bottom near $36/share sometime in the coming quarter; if so then I will revisit the numbers on Citigroup and consider an entry there. (P.S. It's also worth pointing out that under normal market conditions, Citi's sales and earnings appear to grow linearly in dollar terms, which means that growth decelerates over time in percentage terms. In other words, Citigroup is not a compounder. That's reason enough to only trade this stock, not buy-and-hold for the long term.)
NYSE:C
by ChristopherCarrollSmith
14
AUDNZD - ABC Correction In PlayHello traders, Australia has just moved Melbourne back into stage 3 lockdown for an additional 6 weeks. The AUD has performed extremely well over the past month due to the market pricing in an economic recovery. If other governments feel pressured to copy Victoria we could be set for a second lockdown in numerous parts of the world. This suggests the AUD may come under pressure in the near future. We are now looking to go short on the AUDNZD. From a technical perspective there is a head and shoulders set up in play and an ABC correction from the 5 wave structure higher. Any thoughts or comments please let us know.
Short
by Trading_Tony
ridethepig | Gilead to ATH's with Remdesivir📍 The effect of Remdesivir... The power to unlock the all time highs via Covid is systematically, within reach rather fast, due to the nature of drug prices which are inelastic. The effect of Gilead being treated as utility is heightened by DT putting the big orders in. Compare the following two diagrams: Phase III trials & Chinese red carpet Buyers maintaining a strong floor. In the first, you will notice how once we got the break of the channel buyers were allowed to go wandering all the way to the target on grounds of safety! The second wave looks inevitable despite the political fairydust around re-openings, stimulus is running out and now the attempt to reinstate pockets of further lockdowns will make activity immovable. Thus the question, why adding more Gilead? When building a long/short portfolio, we must add hedges and blocks accordingly. The strategic protection with Gilead is pragmatic, 450 million new customers unlocked via European clearance & we already got the ✅ for the red carpet from China. Complacency around the virus is remarkable, UK cheerleading "Super Saturday" and US "Independence Day" ... who would have thought we are in the middle of a pandemic. In any case... An attractive constellation for a swing towards all time highs. Thanks as usual for keeping the feedback coming 👍 or 👎
NASDAQ:GILDLong
by ridethepig
7
XSPA ready (Golden Cross)XSPA began it's pilot covid-19 testing program this week in contract and in conjunction with JFK airport. More airports to follow and getting lots of media attention. XSPA was featured in a time magazine article today. I am long with an avg of $4.71. My price targets for the year are marked. I believe these will be hit by end of year. I will take profit at each target and at any time I may sell my entire position and look for an opportunity to reposition. Trade carefully. Yea I know I am crazy. GLTA. Not Financial Advice Not a recommendation to buy this stock
XLong
by UnknownUnicorn6673904
Break current triangle followed by lengthened market cycleLooking at logarithmic progressions has me thinking that it might be possible that we find support on the line we just broke followed by establishing a slightly higher high followed by undulating smaller pump/dumps that correlate with past events. We form a new upper resistance and therefore a new structure, we break out of this 4-5 years down the road. The market cycles are going to level out as time goes on in terms of highs and lows resulting in a more stable coin IF BTC doesnt become obsolete before then. I think this summer could be good for BTC and the market. Economy will open up, containment of virus will differ depending on country/state/province. Summer usually knocks case numbers down for respiratory illness due to high temps, humidity, and elevated levels of vitamin D, physical activity, spending more times in open spaces. Offices also won't be in a hurry to open back up due to the inability for them to justify moving admin and other office worker resources back into huge office buildings when they can just as easily work from home. Also, the logistics in using elevators, lobbies, and other areas while maintaining any level of social distance is extremely daunting and expensive. I think these factors will result in a less "spready" second wave. This adds up to the irrational, illogical market continuing to pump over the summer. The second COVID wave , in the fall/winter will likely bring another market correction with it, which will drag BTC with it. Also, ppl are on the media at these protests yelling "buy BTC, fight the power" at the camera, any publicity is good publicity, I guess. Summer=Pump, Fall/winter = Dump and or consolidation I think we'll continue to undulate, consolidate, slowly ascend into breaking a larger, future structure. Big, rambly, speculative, but I think a lot of what happens in all markets will be the result of COVID and COVID related responses from govs/industry. These are sort of predictable based on what we know about similar viruses and how govs and market has responded up until now. Whatcha think?
BITSTAMP:BTCUSDLong
by Tobi_Wan_Kenobi